Do you want to read an article? Please log in or register.
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial
Diabetes and Pregnancy
COMMENTED
Related content
Obesity and Bariatric Surgery
Effect of metformin in addition to dietary and lifestyle advice for pregnant women who are overweight or obese: the GRoW randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol.
Dodd JM, Louise J, Deussen AR, Grivell RM, Dekker G, McPhee AJ, Hague W.
doi: 10.1016/S2213-
COMMENTED
Type 2 DiabetesGlycemic Control
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, Fantus IG, Hutton E, Armson AB, Lipscombe LL, Simmons D, Barrett JFR, Karanicolas PJ, Tobin S, McIntyre HD, Tian SY, Tomlinson G, Murphy KE, MiTy Collaborative Group.
doi: 10.1016/S2213-8587(20)30310-7
COMMENTED
Further Publications
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial
★ 3
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.1016/S2213-8587(20)30021-8.
Diabetes - General
Licogliflozin versus placebo in women with polycystic ovary syndrome (PCOS): a randomised, double-blind, phase 2 trial
Diabetes Obes Metab
Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D, Dunschen K, Zakaria M, Huseinovic N, Basson CT, Mahling P, Fuhrer D, Hinder M
doi: 10.1111/dom.14495
Diabetes - GeneralType 1 DiabetesGlycemic Control
Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
Lancet Diabetes Endocrinol.
Petrie JR, Chaturvedi N, Ford I, Brouwers MCGJ, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BEK, Klein R, Ooi TC, Rossing P, Stehouwer CDA, Sattar N, Colhoun HM; REMOVAL Study Group
doi: 10.1016/
Type 2 Diabetes
Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
Diabetes Obes Metab
Weng J, Zeng L, Zhang Y, Qu S, Wang X, Li P, Fu L, Ma B, Ye S, Sun J, Lu W, Liu Z, Chen D, Cheng Z, Liu H, Zhang T, Zou J
doi: 10.1111/dom.14389
Type 1 Diabetes
Insulin Resistance in Type 1 Diabetes Managed with Metformin (INTIMET): study protocol of a double-blind placebo-controlled, randomised trial
Diabet Med
Snaith JR, Samocha-Bonet D, Evans J, Liu Z, Kowalski G, Bruce C, Holmes-Walker DJ, Greenfield JR
doi: 10.1111/dme.14564
Diabetes - GeneralType 2 DiabetesGlycemic Control
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Lancet Diabetes Endocrinol.
Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, Bain SC
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesGlycemic Control
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Lancet Diabetes Endocrinol.
Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, García-Pérez LE, Woodward DB, Milicevic Z
doi: 10.1016/S2213-8587